From the Journals

Personalizing Steroid Duration in Asthma

Researchers tested whether a readily available biomarker can individualize systemic corticosteroid prescribing during asthma-related hospitalizations.

Share

A study conducted in Singapore evaluated the efficacy of using baseline blood eosinophil counts to guide systemic corticosteroid treatment duration in hospitalized asthma patients. The randomized trial involved 110 adults and found that tailoring corticosteroid length based on eosinophil levels achieved similar clinical outcomes while significantly reducing steroid exposure for noneosinophilic patients. The treatment strategy yielded only slightly higher treatment failure rates compared to standard care, with no severe complications noted, indicating a promising approach for managing asthma exacerbations.

Original Source(s)

Personalizing Steroid Duration in Asthma

Researchers tested whether a readily available biomarker can individualize systemic corticosteroid prescribing during asthma-related hospitalizations.

  • by Kathryn Wighton

  • February 3, 2026

  • 3 min

Related Content

A Persistent Cough and an Unexplained Diagnosis

NEJM case details the diagnostic evaluation of an 80-year-old woman with weeks of respiratory symptoms, weight loss, and diffuse ground-glass opacities on chest CT.

New Vaccine Prevents Severe RSV Illness

A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

Mepolizumab Reduces COPD Flares in Eosinophilic Patients

A new clinical trial found that adding mepolizumab to standard inhaled therapy significantly reduced moderate or severe COPD exacerbations in patients with high eosinophil counts, with a 21% lower annual rate and longer time to first flare.